Spero Therapeutics Inc
SPRO2.500USD
+0.370+17.37%
Close 05/30, 16:00（ET）Quotes delayed by 15 min
139.75MMarket Cap
LossP/E TTM
More Details of Spero Therapeutics Inc Company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Company Info
Company codeSPRO
Company nameSpero Therapeutics Inc
IPO dateNov 02, 2017
Founded at2013
CEOMs. Esther Rajavelu
Number of employees32
Security typeOrdinary Share
Fiscal year-endNov 02
Address675 Massachusetts Ave Ste 14
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02139-3309
Phone18572421600
Websitehttps://sperotherapeutics.com/
Company codeSPRO
IPO dateNov 02, 2017
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
+57.14%
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. Patrick Volkert Jo Vink, M.D.
Dr. Patrick Volkert Jo Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Revenue Breakdown
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
47.98M
0.00%
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
Shareholder Statistics
Shareholder
Proportion
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
Type
Shareholder
Proportion
Corporation
20.66%
Hedge Fund
10.30%
Investment Advisor/Hedge Fund
8.22%
Individual Investor
3.66%
Venture Capital
2.58%
Investment Advisor
2.01%
Research Firm
0.14%
Other
52.43%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
114
27.91M
50.02%
+3.00M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
2023Q1
242
24.74M
47.38%
-2.46M
2022Q4
247
26.52M
54.04%
-1.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GSK plc
9.19M
16.44%
--
--
Mar 27, 2025
Anson Funds Management LP.
3.84M
6.87%
+89.44K
+2.38%
Dec 31, 2024
Pfizer Inc
2.36M
4.23%
+2.36M
--
Dec 31, 2024
The Vanguard Group, Inc.
1.76M
3.15%
--
--
Dec 31, 2024
Renaissance Technologies LLC
1.11M
1.98%
+130.94K
+13.43%
Dec 31, 2024
Alphabet, Inc.
889.98K
1.59%
--
--
Dec 31, 2024
Murchinson Ltd.
873.91K
1.56%
+873.91K
--
Dec 31, 2024
Acadian Asset Management LLC
1.04M
1.86%
-31.94K
-2.98%
Dec 31, 2024
Adar1 Capital Management LLC
801.28K
1.43%
+57.82K
+7.78%
Dec 31, 2024
Hamed (Kamal)
788.12K
1.41%
+211.66K
+36.72%
Feb 02, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
